The estimated Net Worth of Jeffrey Wayne Church is at least $820 Mille dollars as of 19 June 2019. Mr. Church owns over 5,000 units of Imunon Inc stock worth over $14,304 and over the last 18 years he sold CLSN stock worth over $0. In addition, he makes $805,543 as Chief Financial Officer, Senior Vice President, Corporate Secretary e IR Contact Officer at Imunon Inc.
Sign up
Mr. Church CLSN stock SEC Form 4 insiders trading
Jeffrey has made over 3 trades of the Imunon Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of CLSN stock worth $9,450 on 19 June 2019.
The largest trade he's ever made was buying 5,000 units of Imunon Inc stock on 19 June 2019 worth over $9,450. On average, Jeffrey trades about 402 units every 113 days since 2007. As of 19 June 2019 he still owns at least 7,298 units of Imunon Inc stock.
You can see the complete history of Mr. Church stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jeffrey Church biography
Jeffrey W. Church , CPA., is Chief Financial Officer, Senior Vice President, Corporate Secretary and IR Contact Officer of Celsion Corporation. Mr. Church was appointed as Senior Vice President, Corporate Strategy and Investor Relations effective July 8, 2011. On July 1, 2014, Mr. Church was reappointed as Senior Vice President and Chief Financial Officer. Immediately prior to joining Celsion, Mr. Church served as Chief Financial Officer and Corporate Secretary of Alba Therapeutics Corporation, a privately held life science company from 2007 until 2010. From 2006 until 2007, he served as Vice President, CFO and Corporate Secretary for Novavax, Inc., a vaccine development company listed on The NASDAQ Global Select Market. From 1998 until 2006, he served as Vice President, CFO and Corporate Secretary for GenVec, Inc., a life science and biotechnology company listed on The NASDAQ Capital Market. Prior to that, he held senior financial positions at BioSpherics Corporation and Meridian Medical Technologies, both publicly traded companies. He started his career with Price Waterhouse from 1979 until 1986. Mr. Church holds a B.S. degree in accounting from the University of Maryland and is a Certified Public Accountant.
What is the salary of Jeffrey Church?
As the Chief Financial Officer, Senior Vice President, Corporate Secretary e IR Contact Officer of Imunon Inc, the total compensation of Jeffrey Church at Imunon Inc is $805,543. There are 3 executives at Imunon Inc getting paid more, with Michael Tardugno having the highest compensation of $1,694,790.
How old is Jeffrey Church?
Jeffrey Church is 58, he's been the Chief Financial Officer, Senior Vice President, Corporate Secretary e IR Contact Officer of Imunon Inc since 2014. There are 11 older and 2 younger executives at Imunon Inc. The oldest executive at Imunon Inc is Michael H. Tardugno, 70, who is the Exec. Chairman, Pres & CEO.
What's Jeffrey Church's mailing address?
Jeffrey's mailing address filed with the SEC is C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ, 08648.
Insiders trading at Imunon Inc
Over the last 17 years, insiders at Imunon Inc have traded over $895,739 worth of Imunon Inc stock and bought 973,579 units worth $2,229,348 . The most active insiders traders include Gary W Pace, Max Link e Sean F. Moran. On average, Imunon Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,407. The most recent stock trade was executed by Michael H Tardugno on 12 April 2022, trading 4,000 units of CLSN stock currently worth $14,120.
What does Imunon Inc do?
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
What does Imunon Inc's logo look like?
Complete history of Mr. Church stock trades at Imunon Inc e Novavax
Imunon Inc executives and stock owners
Imunon Inc executives and other stock owners filed with the SEC include:
-
Michael Tardugno,
Executive Chairman of the Board, President, Chief Executive Officer -
Michael H. Tardugno,
Exec. Chairman, Pres & CEO -
Nicholas Borys,
Senior Vice President and Chief Medical Officer -
Jeffrey Church,
Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer -
Dr. Nicholas Borys,
Exec. VP & Chief Medical Officer -
Jeffrey W. Church CPA, CPA,
CFO, Exec. VP & Corp. Sec. -
Dr. Khursheed Anwer M.B.A., Ph.D.,
Exec. VP & Chief Scientific Officer -
Khursheed Anwer,
Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy -
Dr. Khursheed Anwer,
Exec. VP & Chief Scientific Officer -
Andreas Voss,
Independent Director -
Alberto Martinez,
Independent Director -
Robert Hooper,
Independent Director -
Frederick Fritz,
Independent Director -
Pok Yu Chow,
Independent Director -
Donald Braun,
Independent Director -
Marianne M. Lambertson,
VP of Communications & Investor Relations -
Timothy J. Tumminello,
Chief Accounting Officer & Controller -
Sean F. Moran,
Chief Financial Officer -
Gary W Pace,
Director -
Stacy Lindborg,
Director -
Christine A Pellizzari,
Director -
Timothy J Tumminello,
Controller -
Inc. Fka Egen, Inc. Egwu,,
10% owner -
Max Link,
Director -
Gregory L Weaver,
Director -
Goff Corinne Le,
President and CEO -
Constantine John Kardaras,
Chief Accounting Officer